The World Health Organization projects a significant demographic shift, with the number of people aged 60 and above expected to double by 2050, reaching 2.1 billion from 1 billion in 2020. This trend highlights the growing demand for healthy aging solutions, and technology plays a crucial role in meeting this need.
The longevity biotech industry is experiencing a surge. Numerous companies, some leveraging artificial intelligence, are advancing research in this field. However, there is still a lot to be done in terms of transforming scientific advances into practical clinical interventions and finding common ground when speaking to the FDA.
Recently, LongeVC's Sergey Jakimov and Artem Trotsyuk joined a discussion with Brian Buntz from Drug Discovery to explore these topics. They also shared insights into LongeVC's portfolio companies, the fund's investment focus, the criteria for evaluating new startups, and how to distinguish legitimate applications from “snake oil” in the industry.
Read the full piece here.
The longevity biotech industry is experiencing a surge. Numerous companies, some leveraging artificial intelligence, are advancing research in this field. However, there is still a lot to be done in terms of transforming scientific advances into practical clinical interventions and finding common ground when speaking to the FDA.
Recently, LongeVC's Sergey Jakimov and Artem Trotsyuk joined a discussion with Brian Buntz from Drug Discovery to explore these topics. They also shared insights into LongeVC's portfolio companies, the fund's investment focus, the criteria for evaluating new startups, and how to distinguish legitimate applications from “snake oil” in the industry.
Read the full piece here.